Lazcluze
What Lazcluze is used for
Lazcluze in combination with amivantamab is indicated for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Lazcluze
- Active substance
- lazertinib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01EB09
- Marketing authorisation holder
- Janssen Cilag International NV
- Authorised in the EU since
- 2025
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lazcluze used for?
Lazcluze in combination with amivantamab is indicated for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
What is the active substance in Lazcluze?
Lazcluze contains lazertinib.
Who makes Lazcluze?
The EU marketing authorisation holder is Janssen Cilag International NV.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU